How I Treat Non-Hodgkin Lymphomas: What Tests Do I Run to Diagnose and Follow Patients Across the NHL Spectrum?
Brad Kahl, MD, Washington University in St. Louis
Saturday, September 9, 2017 7:40 a.m.
Fairmont Chicago, Millennium Park, Chicago, IL
Given the large number of lymphoma subtypes, with differing natural histories, one can no longer take a "one-size-fits all” approach to the diagnosis, staging, and follow up. This session will review evidence based strategies for obtaining appropriate tests for the most common lymphoma subtypes. Areas of controversy will be highlighted for discussion.
About the Speaker
Brad Kahl, MD, is a clinical/translational researcher focused on the development of novel agents and strategies for the treatment of lymphoma. He directed the University of Wisconsin Lymphoma Program from 2001 to 2015 and became the Skoronski Chair of Lymphoma Research at the UW Carbone Cancer Center in 2012. Based upon his accomplishments, he was selected as Chairman of the Eastern Cooperative Oncology Group Lymphoma Committee in 2009, where he has facilitated the development of multiple large scale clinical trials, helped successfully renew the ECOG scientific operations grant in 2010, and led a successful effort to obtain a National Clinical Trials Network (NCTN) Lead Academic Performance Site (LAPS) U10 award for the University of Wisconsin in 2013. Dr. Kahl has extensive research administrative experience, serving as Associate Director for Clinical Research in the UW Carbone Cancer Center from 2009 to 2015. In 2015, he joined the faculty at Washington University in St. Louis to become the Director of the Lymphoma Program. Between his faculty appointment, ECOG role, and LRF role, Dr. Kahl regularly provides clinical research and career mentorship to fellows and junior faculty. He has participated in the LRF clinical trials workshop since its conception and looks forward to ongoing participation as a member of the faculty.
back to top